91182-60-4

Usage

Uses

Used in Pharmaceutical Industry:
5-(4-Bromo-phenyl)-3-methyl-isoxazole-4-carboxylic acid is used as an intermediate in the synthesis of various pharmaceuticals for its potential pharmacological properties. It is being researched for its anti-inflammatory and antifungal activities, making it a valuable component in the development of new medications targeting these conditions.
Used in Agrochemical Industry:
In the agrochemical sector, 5-(4-Bromo-phenyl)-3-methyl-isoxazole-4-carboxylic acid serves as a key intermediate in the production of agrochemicals. Its unique chemical structure allows for the creation of compounds with specific pesticidal or herbicidal properties, contributing to the development of effective crop protection agents.
Used in Neurological Disorder Treatment Research:
5-(4-Bromo-phenyl)-3-methyl-isoxazole-4-carboxylic acid is also being explored for its potential in the treatment of neurological disorders. Its pharmacological profile suggests that it may have neuroprotective or disease-modifying effects, warranting further investigation into its therapeutic applications for conditions such as Alzheimer's, Parkinson's, or other neurodegenerative diseases.
Overall, 5-(4-Bromo-phenyl)-3-methyl-isoxazole-4-carboxylic acid is a versatile chemical entity with a broad spectrum of potential applications across different industries, particularly in the development of new therapeutic agents and agrochemicals. Its ongoing research and development underscore its importance in the scientific community.

InChI:InChI=1S/C11H8BrNO3/c1-6-9(11(14)15)10(16-13-6)7-2-4-8(12)5-3-7/h2-5H,1H3,(H,14,15)

Upstream product

• 893643-73-7 2-(4-bromobenzoyl)-3-carbonylbutyrate ethyl ester 
• 917388-58-0 5-(4-bromophenyl)-3-methylisoxazole-4-carboxylic acid ethyl ester 
• 1228689-61-9 methyl 5-(4-bromophenyl)-3-methylisoxazole-4-carboxylate 
• 85963-90-2 methyl 2-(4-bromobenzoyl)-3-oxo-butanoate 
• 586-76-5 4-Bromobenzoic acid 
• 586-75-4 4-chlorobenzoyl chloride 
• 1423699-80-2 C₁₃H₁₄BrNO₃ 

Downstream Products

• 1280205-93-7 5-(4-bromo-phenyl)-3-methyl-isoxazol-4-ylamine 
• 1280206-00-9 [5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-(3-phenyl-propyl)-amine 
• 1280206-03-2 [5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-[3-(4-isopropyl-phenyl)-2-methyl-propyl]-amine 
• 1280208-00-5 2-benzylsulfanyl-1-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-ethanone 
• 1280208-02-7 2-Bromo-1-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]ethanone 
• 1228690-36-5 AM₀₉₅ 
• 1228690-38-7 {4'-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-biphenyl-4-yl}-acetic acid ethyl ester 
• 1345614-59-6 (2-[4-[4-[3-methyl-4-[[(1R)-1-phenylethoxy]carbonylamino]-1,2-oxazol-5-yl]phenyl]phenyl]acetic acid) sodium salt 
• 1280205-98-2 (5-(4-bromophenyl)-3-methylisoxazole-4-yl)methanol 
• 1380650-63-4 1-{4'-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester 

Relevant academic research and scientific papers

Lysophosphatidic acid receptor antagonists and preparation method thereof

The invention belongs to the technical field of medicinal chemistry, and particularly relates to lysophosphatidic acid receptor antagonists and a preparation method thereof. The applicant surprisinglyfinds that compounds provided by the invention have high LPAR1 antagonistic activity and selectivity, low toxicity, good metabolic stability and good drug development prospect, and can be used for preventing or treating diseases or symptoms related to LPAR1. The applicant also accidentally finds that the IC50 value of part of the compounds can be as low as 300 nM or below and even 50 nM or below.Moreover, the compounds disclosed by the invention have better safety, and the CC50 range of the compounds can reach 200 [mu]M or above. In addition, the compounds of the present invention have goodmetabolic stability in humans, rats, and mice, such excellent inhibitory activity being very desirable for their use as LPAR1 inhibitors in the above diseases or disorders. In addition, the preparation method of the compounds is simple, mild in reaction condition, high in product yield and suitable for industrial production.

LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS

Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders, or conditions associated with one or more of the lysophosphatidic acid receptors are provided.

POLYCYCLIC LPA1 ANTAGONIST AND USES THEREOF

Described herein is the LPA1 antagonist 1- {4'-[3-methyl-4-((R)- l-phenyl-ethoxycarbonylamino)- isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1), or pharmaceutically acceptable salts thereof. Also described are methods of preparing t

LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS

Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in com

LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONIST AND USES THEREOF

Described herein is the LPAl antagonist {4'-[3-methyl-4-((R)-l-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-biphenyl-4-yl}-acetic acid (Compound 1), including pharmaceutically acceptable salts thereof. Also described are methods of preparing the LPAl antago

POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS

Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.

Compounds as Lysophosphatidic Acid Receptor Antagonists

Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in com

ALKYNE ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS

Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in com

ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS

Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.

POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS

Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.